Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India

Sanat Phatak1,2 · Aditya Khenat2 · Mansi Malandkar3 · Sanjiv Amin3

Received: 1 April 2022 / Revised: 28 April 2022 / Accepted: 8 May 2022 / Published online: 21 May 2022 © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022

Abstract
Generic tofacitinib has been available in India for more than a year and is widely used in rheumatoid arthritis (RA) therapy. There is scarce real-world data on its effectiveness and safety from India, especially given infection endemcity. We retrospectively analysed records (demographic and clinical information, haematology and biochemistry, adverse events) of patients prescribed generic tofacitinib from a single centre in Mumbai, India. Disease activity was calculated using the disease activity score-28 and erythrocyte sedimentation rate (DAS28-ESR) and other tools, and we used paired T-tests for significant response. We defined clinical tofacitinib failure as a composite outcome, including clinician’s decision to change to an alternative disease-modifying anti-rheumatic drug (DMARD) or flare after self-withdrawal. We performed logistic regression and survival analysis for determinants of clinical failure. We reviewed records of 102 patients (92 female; median age: 53 years) with mean RA duration of 146 months. Thirteen had prior treatment with innovator tofacitinib. There was significant improvement in disease activity parameters at a mean duration of 186 days. No serious adverse events were reported; 4 patients had tuberculosis and 19 patients had mild COVID-19 while on treatment. Clinical failure was seen in 25 patients, and mean time to failure on survival analysis was 357 days. No baseline characteristic predicted clinical failure. Generic tofacitinib showed good effectiveness and a tolerable adverse effect profile, despite tuberculosis endemicity and COVID-19. Setting up registries would be valuable in gaining more data on generic tofacitinib.

Key Points
• There is scarce data from India regarding the use of tofacitinib in rheumatoid arthritis, despite widespread use.
• In this retrospective analysis of 102 patients at a single centre, we found tofacitinib monotherapy was efficacious and tolerable.
• Tuberculosis was detected in four and nineteen patients had mild covid.

Keywords
Generic · Registry · Rheumatoid arthritis · South Asia · Tofacitinib

Introduction
The therapeutic armamentarium of rheumatoid arthritis (RA) has been enriched considerably with the addition of targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs), including the oral selective Janus kinase (JAK1/JAK3) inhibitor tofacitinib. [1] Multiple large clinical trials and follow-up studies have established the efficacy and safety of tofacitinib in RA. [2-5] The United States Food and Drug Administration (US-FDA) approved its use for RA in 2012. [6]

RA in Asian regions differs due to different disease prevalence, adverse effect profiles and socio-economic determinants that impact management. India is endemic for tuberculosis (TB) and has seen multiple waves of the recent COVID-19 pandemic. [7] Compared with European ethnic groups, Indians have higher metabolic disease susceptibility, [8] which JAK inhibition may worsen.
There are limited data on the use of tofacitinib in India. Indian patients included in the clinical trials of the innovator tofacitinib were found to have similar efficacy but a different infection profile, (primarily TB) in a post hoc analysis. [9] While randomised controlled trials (RCTs) provide high-quality data that show evidence of causality, they are artificial environments with strict inclusion criteria, close follow-up and monitoring, and fewer comorbidities. [10] Consequently, the interpretability of the results to real-world patients is compromised, a gap bridged by observational studies and registries. [11] Most observational data on tofacitinib comes from the USA, where tofacitinib has been available since 2012.

Despite the dearth of information on tofacitinib in Indian patients, paradoxically, there has been an increase in its use recently in India. Though innovator tofacitinib has been available in India since June 2016, generic tofacitinib was introduced in November 2020, reducing the monthly therapy cost approximately tenfold. To the best of our knowledge, there is no real-world observational study of the effectiveness and tolerability of generic tofacitinib from India. We conducted a retrospective analysis of patients prescribed generic tofacitinib from a single centre in western India, and report on its efficacy and safety.

Methods

We reviewed electronic health records of consecutive patients with RA who received tofacitinib, at an independent private rheumatology clinic in Mumbai, India, who were receiving generic tofacitinib. Tofacitinib (manufactured by Cipla, Ltd) was given as monotherapy, started mainly due to suboptimal response to previous therapy, economic considerations or convenience of oral medications in comparison with biologic DMARDs (bDMARDs). Active TB (X-ray), hepatitis B (HBsAg and IgM anti-HBc) and hepatitis C infection (anti-HCV) were ruled out prior to starting the medication.

Data collection Clinical information at the time of presentation as well as the date of initiation of tofacitinib, including comorbidities, anthropometry, haematological and serological, was retrieved from electronic records. This was supplemented as necessary by personal interviews or phone calls, especially regarding adverse effects of medications and intercurrent infections.

Clinical assessments All clinical assessments at each visit were performed by the same clinician. Rheumatoid factor and C-reactive protein (CRP) were measured by immunoturbidimetry, anti-CCP (anti-cyclic citrullinated peptides) antibodies by the ELISA method, and erythrocyte sedimentation rate (ESR) by the Westergren method.

Outcome measures For RA disease activity, composite scores, including disease activity score-28 (DAS28), simplified disease activity index (SDAI) and clinical disease activity index (CDAI), were calculated. DAS28 disease activity and the responders were defined as per the European Alliance of Associations for Rheumatology (EULAR) response criteria.

Drug failure We defined clinical tofacitinib failure as a composite outcome based on the clinician’s decision to change to an alternative DMARD due to non-response or disease flare after patient’s self-withdrawal.

Statistical analysis

Data are presented as frequencies, mean or median, depending upon the type of data. Response to tofacitinib on various parameters was calculated using paired T-tests to detect differences at onset and last follow-up. We then grouped the patients according to low baseline disease activity (EULAR remission or mild disease activity, DAS28 < 3.2) and moderate-to-high disease activity (EULAR moderate and high disease activity, DAS28 > 3.2) and repeated paired T-tests separately in these subgroups. Logistic regression analyses were performed to evaluate factors associated with tofacitinib clinical failure. For the regression analysis, we included age, body size measurements, duration of disease, baseline disease activity, presence or absence of comorbidities, prior bDMARD exposure, and baseline disease activity as dependent variables. A survival analysis was performed to assess the mean time to clinical failure.

Ethics

This study received ethics permission from an independent ethics committee who accorded a consent waiver. Confidentiality was maintained using unique identifiers.

Results

Patient characteristics

We studied 102 patients (92 females; median age 53 years) (Table 1). Average body mass index (BMI) was 26 ± 7 (37 were overweight, 14 obese). Hypertension was the most common comorbidity (n = 29). The mean duration of disease was 146 months and mean DAS28-ESR was 4.79 (1.54). Two-thirds of patients had fatigue and weight loss. Five had
Tofacitinib treatment

Eighty-four were switched over to generic tofacitinib monotherapy from previous therapy and 13 from innovator tofacitinib while 5 patients were treatment naive (Table 1). First DMARD received was methotrexate (n = 81), sulphasalazine (n = 16) and leflunomide (3). Seventy-four had received two DMARDs. Twenty-nine patients had received at least one bDMARD (20 had TNF α inhibitors, tocilizumab (n = 6) and rituximab (n = 3)); 12 had received two bDMARDs. No patients were on glucocorticoids at the time of switching, or while on tofacitinib.

### Table 1 Baseline characteristics of patients with RA at initiation of generic tofacitinib (n = 102)

| Characteristics | Value |
|-----------------|-------|
| Gender ratio    | Male: 10, female: 92 |
| Age, years (median, range) | 53 (21–83) |
| Weight, kg (mean, SD) | 61 (13.9) |
| Height, cm (mean, SD) | 155.9 (7.0) |
| BMI, kg/m² (mean, SD) | 26 (7.0) |
| Comorbidities (n) | None: 47, Hypertension: 29, Type 2 diabetes: 9, Hypothyroidism: 12, Bronchial asthma: 1, Others: 4 |
| RA disease duration, months (median, range) | 146 (9–520) |
| DAS28-ESR (mean, SD) | 4.79 (1.54) |
| EULAR disease activity according to DAS28-ESR (n) | Remission (<2.6): 9, Mild (2.6–3.2): 7, Moderate (3.2–5.1): 45, Severe (>5.1): 41 |
| CDAI (median, range) | 19 (2–60) |
| SDAI (median, range) | 24 (2.4–160) |
| CRP, mg/dL (mean, SD) | 14.3 (22.1) |
| ESR, mm (mean, SD) | 43 (28) |
| Prior treatment (n) | Treatment naïve: 5, csDMARDs only: 64, csDMARDs + bDMARDs or bDMARDs only: 20, csDMARDs + bDMARD + tsDMARD or csDMARDs + tsDMARD: 13 |

*Body mass index categories (n) < 18.5 (6); 18.5–24.9 (45); 25–29.9 (37); > 30 (14) csDMARDs (methotrexate, leflunomide, sulfasalazine, hydroxychloroquine); bDMARDs: (adalimumab, infliximab, tocilizumab, etanercept, rituximab); tsDMARD: tofacitinib (innovator) |

### Treatment with tofacitinib generic

Tofacitinib was prescribed in a dose of 5 mg twice a day. Mean duration of therapy was 186 (74–505) days at evaluation. As a group, the patients responded well; significant differences were observed in most disease activity-related parameters (Table 2). DAS28 responses correlated well with SDAI (r² of 0.815, p = 0.000). Forty-seven classified as DAS28 responders. CRP levels, but not ESR, significantly reduced.

These improvements were driven by patients who were switched from other DMARDS (n = 89): in these patients, the DAS28-ESR fell from 4.87 to 4.34 (p = 0.00), SDAI fell from 34.3 to 25 (p = 0.009), and CDAI fell from 22 to 15 (p = 0.007). Patients who were switched to generic tofacitinib from innovator tofacitinib (n = 13) did not have a statistically significant change in disease activity parameters (DAS28: 4.2 to 3.8, p = 0.328; SDAI 34 to 21; p = 0.146) apart from CDAI (16 to 10, p = 0.03). There was no correlation between prior treatment and tofacitinib response.

Patients who had moderate-to-high disease activity at baseline (DAS28 > 3.2, n = 86) improved in all disease-related parameters (Table 2). Disease activity increased (mean DAS28 rise 1.16) in the 16 patients who had low disease activity at baseline (DAS28 < 3.2). As a group, the patients responded well; significant differences were observed in most disease activity-related parameters (Table 2). DAS28 responses correlated well with SDAI (r² of 0.815, p = 0.000). Forty-seven classified as DAS28 responders. CRP levels, but not ESR, significantly reduced.

### Adverse events

Fourteen out of 102 patients experienced adverse events (all minor). Most reported AE were GI disorders, paraesthesia, rash, and itching (Table 4). Two patients had unusual manifestations: claudication and panniculitis. No serious adverse events (thrombosis, cardiovascular events, malignancies, etc.) were seen.

### Table 2 Response to generic tofacitinib

| Parameter | At onset (mean ± SD) | At follow-up (mean ± SD) | Significance p-value |
|-----------|----------------------|--------------------------|----------------------|
| TJC       | 9 ± 7.8              | 5.2 ± 5.7                | 0.000                |
| SJC       | 3.4 ± 4.3            | 1.3 ± 2.3                | 0.000                |
| DAS28     | 4.79 ± 1.54          | 4.27 ± 1.4               | 0.002                |
| SDAI      | 34.4 ± 28.4          | 24.4 ± 20.3              | 0.001                |
| CDAI      | 21.4 ± 13.4          | 15.1 ± 11.2              | 0.000                |
| Weight    | 61 ± 13.9            | 64 ± 14.0                | 0.000                |
| Laboratory investigations | | | |
| CRP       | 14.3 ± 22.1          | 10.6 ± 13.9              | 0.005                |
| ESR       | 43 ± 28              | 42 ± 28                  | 0.799                |
| Hb        | 11.2 ± 1.47          | 11.2 ± 1.42              | 0.764                |
| WBC       | 7004 ± 2399          | 7233 ± 2194              | 0.211                |
| Creatinine| 0.7 ± 0.19           | 0.82 ± 0.32              | 0.044                |
| Cholesterol| 174 ± 34             | 192 ± 39.6               | 0.000                |
| SGPT      | 21.6 ± 12.1          | 20.8 ± 10.7              | 0.533                |
mortality) were reported. Four reported TB; tofacitinib was not stopped in these patients, and anti-TB therapy was given. In 19 patients, a positive SARS-CoV2 nasal RT-PCR was reported while on tofacitinib. All COVID-19 infections were mild, and none required hospitalisation. Tofacitinib was not stopped in any of these patients by the physician. There was no reported case of severe viral infection or herpes zoster in this cohort.

### Metabolic and haematologic adverse effects

As a group, the patients showed increase in weight (mean: 3 kg) and cholesterol (mean: 18 mg/dL) while on tofacitinib. Increase in cholesterol was seen in both low and high disease activity groups at baseline. There was no significant fall in platelet count.

### Tofacitinib failure

Twenty-five had tofacitinib clinical failure: 21 had inadequate response and were switched to a different medication (18 to baricitinib, 2 to adalimumab, and 1 to combination csDMARD), while 4 had flare of RA after self-withdrawal. In addition to these, tofacitinib was stopped in 1 patient because of pregnancy (not included in failure). Patients who failed to respond to generic tofacitinib showed increased DAS28 and SDAI scores (mean increase: 0.50 and 4.3, respectively). Logistic regression analysis revealed no association of failure with characteristics at baseline (age, duration of disease, previous bDMARD use, disease activity at baseline or body phenotype characteristics). The mean time to clinical failure was 357 days (95% CI: 292–439).

### Discussion

This retrospective real-world study analysing Indian patients with RA treated with generic tofacitinib from a single centre in Western India showed a good response to tofacitinib treatment despite long duration, active disease and multiple DMARD failures. There were no serious adverse events during the treatment; 4 patients had TB. COVID-19 was mild in all affected. One-fourth of the patients had a clinically defined failure, which was not predicted by any baseline characteristics at the time of starting tofacitinib therapy.

Primary clinical trial data about tofacitinib is robust, with the availability of the large ORAL trials. All our patients received tofacitinib monotherapy, like was prescribed in the ORAL-SOLO trial. [12] It was further demonstrated that tofacitinib monotherapy was non-inferior to combination with methotrexate. [4] Though India patients were included in the ORAL trials, they were young and bDMARD naïve. [9] In contrast, our patients had a wider age range, including 12 patients older than 70 years. This is likely to represent a spectrum of disease that is both more heterogeneous and severe than in the trials. Other registries like the CORRONA registry, in which patients on tofacitinib had a disease duration of > 10 years, and others from across the world also represent this cross-section [13–15].

---

**Table 3** Response to generic tofacitinib in patients segregated by baseline disease activity

|                      | At onset Mean ± SD | At follow-up Mean ± SD | Significance (p-value) |
|----------------------|--------------------|------------------------|------------------------|
| Patients with moderate–high baseline disease activity (n = 86) | DAS28 5.23 ± 1.22  | 4.40 ± 1.38            | 0.000                  |
|                      | SDAI 38.6 ± 28.8   | 25.5 ± 21.2            | 0.000                  |
|                      | CDAI 24.1 ± 12.9   | 15.6 ± 11.7            | 0.000                  |
|                      | CRP 16.5 ± 23.5    | 10.9 ± 14.7            | 0.029                  |
|                      | ESR 47.8 ± 27.8    | 46.4 ± 28.7            | 0.643                  |
|                      | Cholesterol 174.2 ± 35.1 | 191.0 ± 40.1         | 0.000                  |
| Patients with low baseline disease activity (n = 16) | DAS28 2.41 ± 0.59  | 3.57 ± 1.3             | 0.003                  |
|                      | SDAI 10.5 ± 5.3    | 18.6 ± 13.3            | 0.055                  |
|                      | CDAI 7.0 ± 2.87    | 12.3 ± 8.13            | 0.370                  |
|                      | CRP 2.97 ± 2.47    | 6.45 ± 7.83            | 0.123                  |
|                      | ESR 20.6 ± 22.2    | 23.8 ± 13.5            | 0.548                  |
|                      | Cholesterol 176.9 ± 33.8 | 198.4 ± 37.4         | 0.015                  |

**Table 4** Safety summary

| Adverse events                        | Tofacitinib generic (n = 102) |
|----------------------------------------|-------------------------------|
| Patients with serious adverse events   | 0                             |
| Patients with adverse events           | 14 (13.75%)                   |
| Claudication improved after omission   | 1 (0.98%)                     |
| Right leg panniculitis                 | 1 (0.98%)                     |
| Eczema                                 | 1 (0.98%)                     |
| Giddiness                              | 1 (0.98%)                     |
| Rash and itching                      | 3 (2.94%)                     |
| Parasthesia                            | 3 (2.94%)                     |
| Gi disorder                            | 4 (3.92%)                     |
| Patients discontinuing due to adverse events | 7 (6.86%)           |
| Discontinue due to pregnancy           | 1 (0.98%)                     |
| Deaths                                 | 0                             |
| Adverse events of special interest     | 0                             |
| Serious infections                     | 0                             |
| Herpes zoster                          | 1 (0.98%)                     |
| Tuberculosis                           | 4 (3.92%)                     |
| MACE                                    | 0                             |
| Thrombosis                             | 0                             |
| Malignancy                             | 0                             |
| Total positive SARS-COV 2/COVID-19 patients in cohort | 19 (18.62%)                 |
Our report of the effectiveness of generic tofacitinib in clinical practice compliments post-marketing studies including participants of varying ethnicities. (14, 16) We found that the response was robust in those who had high disease activity at baseline. In the small number of patients who had low disease activity, the mild increase may represent a regression to the mean. Importantly, the patients who switched from innovator tofacitinib to the generic tofacitinib continued to improve. Although the numbers in this subset are very small to formally evaluate non-inferiority, this is heartening initial data and would benefit from a planned study.

We chose a pragmatic definition of failure based on clinical events, viz. rheumatologist-prescribed change or drug withdrawal flares. We did not use usual definitions based on disease activity scores to simulate usual decision-making in the clinic outside of a formal trial; these scores are seldom calculated and used to make treatment choices. In addition, many patients were already doing well before starting tofacitinib and were moved over due to financial- or convenience-based (oral versus injectable) reasons, thus making the interpretation of change in disease activity scores not representative. This line of reasoning was supported by traditional outcome measures: DAS28 worsened in those who were labelled failures. Failures were often late and, thus, were important to critically evaluate drug response even after initial response; and mean survival was longer than that seen in a European registry (112 days). [16] In other studies, disease duration and the number of prior bDMARDs have been associated with tofacitinib non-response. [13, 14, 17].

All adverse events observed were minor. A recent meta-analysis of 20 trials showed a risk ratio of 2.75 for serious infections, higher in the 20 mg/day dose group. [18] TB was the most common opportunistic infection with 26 events noted in a follow-up of more than 5,000 patients, 80% from countries with a high background incidence of TB. [19] TB incidence was 1.21 per 100 per year in Indian patients from clinical trials; interestingly, all those who developed TB were not amongst the 23 patients who had LTBI on screening. [9] Given our substantive number of TB, screening for LTBI may be prudent in this population.

All COVID-19 were mild in these patients. It is tempting to speculate that the tofacitinib may have helped by modulating the inflammatory pathways that produce lung injury and other complications in COVID-19. [20] We did not stop tofacitinib in these patients during, or after, the course of COVID-19. Our patients also demonstrated the metabolic effects of weight gain [21] and lipid abnormalities [22] seen in other cohorts. Long-term follow-up would help study translation into cardiovascular events, especially when weighed against the increased cardiovascular risk of uncontrolled RA.

To the best of our knowledge, this is the first study reporting the real-world experience of generic tofacitinib from India. Inclusion of patients from a single centre, using tofacitinib monotherapy, a single manufacturer reduced possible confounders. Our study has limitations, viz. durations of treatments differed in patients and the absence of a control group (making attributing causality of both response and AEs difficult). Finally, subgroups (such as patients switching over from innovator tofacitinib) were small, limiting the interpretability of results taken in isolation in these.

In summary, generic tofacitinib demonstrated good effectiveness and a tolerable adverse reaction profile despite the high endemicity of infections in India. These findings make a case for formal long-term real-world studies from India, especially given the widespread use of generic tofacitinib.

Funding Publication was funded by Cipla Ltd, India. The authors were fully responsible for all content and were involved at all stages of development and provided their approval on the final version.

Declarations

Disclosures None.

Data sharing De-identified data will be available with Dr S N Amin for sharing after publication and will be shared depending on the merit and prior approval of proposals. Data requests can be made to drsamin@gmail.com.

References

1. Kawalec P, Śladowksa K, Malinowska-Lipień I, Brzostek T, Kózka M (2017) European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 14:15–29
2. Burmester GR, Blanco R, Charles-Schoeman C et al (2013) ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–60
3. Fleischmann R, Mysler E, Hall S et al (2017) ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457–468
4. Fleischmann R, Wollenhaupt J, Takiya L et al (2017) Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open 3:e000491
5. Smolen JS, Landewé RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699
6. Traynor K (2012) FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 69(24):2120. https://doi.org/10.2146/news120088
7. Lau CS, Chia F, Dans L et al (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22:357–375
8. Rush EC, Freitas I, Plank LD (2009) Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr 102:632–641. https://doi.org/10.1017/S0007114508207221
9. Chopra A, Shobha V, Chandrashekar S et al (2020) Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: a post hoc analysis of efficacy and safety in phase 3 and long-term extension studies over 7 years. Int J Rheum Dis 23:882–897
10. Egger M, Moons KG, Fletcher C (2016) GetReal Workpackage 4 GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Res Synth Methods. 7:278–81
11. Barnish MS, Turner S (2017) The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res 8:49–55
12. Fleischmann R, Kremer J, Cush J, et al (2012) ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 9;367:495–507
13. Kremer JM, Bingham CO 3rd, Cappelli LC et al (2021) Post-approval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based Rheumatoid Arthritis Registry. ACR Open Rheumatol 3:173–184
14. Iwamoto N, Tsuji S, Takatani A et al (2017) Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS ONE 12:e0177057
15. Har nett J, Gerber R, Gruben D, Koenig AS, Chen C (2016) Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. Administrative Claims Database. J Manag Care Spec Pharm 22:1457–1471
16. Mueller RB, Hasler C, Popp F et al (2019) Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med. 8:1548
17. Mori S, Yoshitama T, Ueki Y (2018) Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naive and experienced patients. Intern Med 57:663–670
18. Wang F, Sun L, Wang S et al (2020) Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc 95:1404–1419
19. Winthrop KL, Park SH, Gul A et al (2016) Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:1133–1138
20. Guimarães PO, Quirk D, Furtado RH et al (2021) STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 385:406–415
21. Novikova DS, Udachkina HV, Markelova EI et al (2019) Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int 39:1181–1189
22. Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gómez-Reino JJ (2015) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:117–127

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.